Keyword: Catabasis Pharmaceuticals

Catabasis routed after DMD trial failure

The approval by the FDA last year for Sarepta’s DMD drug Exondys 51 (eteplirsen) buoyed many in this research space, but last night we were all reminded of how tough this disease area can be after Catabasis posted disappointing data for its candidate edasalonexent.